Cargando…
Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556873/ https://www.ncbi.nlm.nih.gov/pubmed/36249800 http://dx.doi.org/10.3389/fphar.2022.1007556 |
_version_ | 1784807172116316160 |
---|---|
author | Yan, Yu-Chen Xu, Zhi-Heng Wang, Jian Yu, Wen-Bo |
author_facet | Yan, Yu-Chen Xu, Zhi-Heng Wang, Jian Yu, Wen-Bo |
author_sort | Yan, Yu-Chen |
collection | PubMed |
description | Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts from Ginkgo biloba folium (GBE) have been shown neuroprotective in PD models. However, the complex GBE extracts intertwingled with complicated PD targets hinder further drug development. In this study, we have pioneered using single-nuclei RNA sequencing data in network pharmacology analysis. Furthermore, high-throughput screening for potent drug-target interaction (DTI) was conducted with a deep learning algorithm, DeepPurpose. The strongest DTIs between ginkgolides and MAPK14 were further validated by molecular docking. This work should help advance the network pharmacology analysis procedure to tackle the limitation of conventional research. Meanwhile, these results should contribute to a better understanding of the complicated mechanisms of GBE in treating PD and lay the theoretical ground for future drug development in PD. |
format | Online Article Text |
id | pubmed-9556873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95568732022-10-14 Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease Yan, Yu-Chen Xu, Zhi-Heng Wang, Jian Yu, Wen-Bo Front Pharmacol Pharmacology Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts from Ginkgo biloba folium (GBE) have been shown neuroprotective in PD models. However, the complex GBE extracts intertwingled with complicated PD targets hinder further drug development. In this study, we have pioneered using single-nuclei RNA sequencing data in network pharmacology analysis. Furthermore, high-throughput screening for potent drug-target interaction (DTI) was conducted with a deep learning algorithm, DeepPurpose. The strongest DTIs between ginkgolides and MAPK14 were further validated by molecular docking. This work should help advance the network pharmacology analysis procedure to tackle the limitation of conventional research. Meanwhile, these results should contribute to a better understanding of the complicated mechanisms of GBE in treating PD and lay the theoretical ground for future drug development in PD. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9556873/ /pubmed/36249800 http://dx.doi.org/10.3389/fphar.2022.1007556 Text en Copyright © 2022 Yan, Xu, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yan, Yu-Chen Xu, Zhi-Heng Wang, Jian Yu, Wen-Bo Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title | Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title_full | Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title_fullStr | Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title_full_unstemmed | Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title_short | Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease |
title_sort | uncovering the pharmacology of ginkgo biloba folium in the cell-type-specific targets of parkinson’s disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556873/ https://www.ncbi.nlm.nih.gov/pubmed/36249800 http://dx.doi.org/10.3389/fphar.2022.1007556 |
work_keys_str_mv | AT yanyuchen uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease AT xuzhiheng uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease AT wangjian uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease AT yuwenbo uncoveringthepharmacologyofginkgobilobafoliuminthecelltypespecifictargetsofparkinsonsdisease |